Sandoz announces plan to improve competitiveness and realign the organization, to drive ongoing Transformation and support future growth

  • Two-stage strategic Transformation plan foresees measures for organizational realignment, followed by increased investments to drive growth segments
  • Realignment of organization involves a planned reduction of global workforce by approximately 900 FTEs, including closure of Holzkirchen development center

HOLZKIRCHEN, May 15, 2019 – Sandoz today announces plans for a leaner and more efficient global organization, to drive cost competitiveness as the first stage of its ongoing strategic Transformation and support investments into future growth. …

/by

Sandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation system

  • Sandoz receives generic approval for Rosuvastatin from China’s National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system
  • Generic approval under China’s recently introduced QCE system is first of a kind for multinational pharmaceutical company
  • Regulatory milestone demonstrates long-term strategic focus on pioneering access to high-quality medicines in world’s largest, and rapidly-growing, generics market

Holzkirchen, Germany, May 9, 2019 – Sandoz today announced that it …

/by

Sandoz demonstrates strategic focus on China, with first-of-a-kind generic approval under Quality Consistency Evaluation system

  • Sandoz receives generic approval for Rosuvastatin from China’s National Medical Products Administration (NMPA) under Quality Consistency Evaluation (QCE) system
  • Generic approval under China’s recently introduced QCE system is first of a kind for multinational pharmaceutical company
  • Regulatory milestone demonstrates long-term strategic focus on pioneering access to high-quality medicines in world’s largest, and rapidly-growing, generics market

Holzkirchen, Germany, May 9, 2019 – Sandoz today announced that it …

/by